Milligan Daun Johnson, Fields Aaron M
San Antonio Uniformed Services Health Education Consortium, Brooke Army Medical Center, Division of Anesthesiology and Critical Care, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA.
Anesthesiol Clin. 2010 Dec;28(4):753-60. doi: 10.1016/j.anclin.2010.08.003.
Levosimendan is a unique therapeutic agent that decreases mortality in acute episodes of decompensated heart failure by increasing myocardial contractility without increasing oxygen consumption or ATP demands, decreasing preload, or decreasing afterload. The mechanism for each accomplishment is novel. The drug is a calcium sensitizer, which increases myocyte contractility by stabilizing troponin C rather than by increasing intracellular calcium. The drug may have implications in numerous other common and chronic medical ailments, even in overdoses of drugs that stun and depress the myocardium.
左西孟旦是一种独特的治疗药物，它通过增强心肌收缩力而不增加氧消耗或ATP需求、降低前负荷或降低后负荷，从而降低失代偿性心力衰竭急性发作时的死亡率。实现这些效果的机制都是新颖的。该药物是一种钙增敏剂，它通过稳定肌钙蛋白C来增强心肌细胞收缩力，而不是通过增加细胞内钙来实现。这种药物可能对许多其他常见和慢性疾病也有影响，甚至对那些使心肌顿抑和抑制心肌的药物过量情况也有作用。
